Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | NVAX |
---|---|---|
09:32 ET | 105455 | 15.7799 |
09:34 ET | 39228 | 15.64 |
09:36 ET | 29662 | 15.7 |
09:38 ET | 33429 | 15.795 |
09:39 ET | 16856 | 15.81 |
09:41 ET | 26577 | 15.7646 |
09:43 ET | 62497 | 15.74 |
09:45 ET | 18308 | 15.9 |
09:48 ET | 69682 | 16 |
09:50 ET | 67832 | 16.11 |
09:52 ET | 40623 | 16.02 |
09:54 ET | 84499 | 16.06 |
09:56 ET | 66388 | 16.18 |
09:57 ET | 60357 | 16.24 |
09:59 ET | 134086 | 16.25 |
10:01 ET | 69015 | 16.378 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Novavax Inc | 2.2B | -5.2x | --- |
PTC Therapeutics Inc | 2.6B | -4.4x | --- |
ACADIA Pharmaceuticals Inc | 3.0B | -1,426.6x | --- |
Azenta Inc | 3.0B | -20.3x | --- |
P3 Health Partners Inc | 209.2M | -1.0x | --- |
Beam Therapeutics Inc | 2.2B | -15.7x | --- |
Novavax, Inc. is a biotechnology company, which discovers, develops and commercializes vaccines to prevent serious infectious diseases. The Company offers a differentiated vaccine platform that combines a recombinant protein approach, advanced nanoparticle technology and its patented Matrix-M adjuvant to enhance the immune response. It has one commercial program, for vaccines to prevent COVID-19, which includes Nuvaxovid prototype COVID-19 vaccine (NVX-CoV2373 or prototype vaccine) and Nuvaxovid updated COVID-19 vaccine (NVX-CoV2601 or updated vaccine) (collectively, COVID-19 Vaccine). The Company is advancing the development of other vaccine candidates, including its COVID19-Influenza Combination (CIC) vaccine candidate and additional vaccine candidates. Its COVID-19 Vaccine and its other vaccine candidates incorporate the Company’s proprietary Matrix-M adjuvant to enhance the immune response and stimulate higher levels of functional antibodies and induce a cellular immune response.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.2B |
---|---|
Revenue (TTM) | $996.6M |
Shares Outstanding | 140.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.98 |
EPS | $-3.18 |
Book Value | $-5.14 |
P/E Ratio | -5.2x |
Price/Sales (TTM) | 2.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -39.99% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.